drugset / Trial / NCT06095206

The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site

NCT06095206

NaSingle-groupOpen-labelOther

Summary

The bioavailability study is intended to evaluate the pharmacokinetic (PK) characteristics and the bioavailability of the two formulations in humans before and after the change of production site, in order to assess the possible impact of the site change on the pharmacokinetic characteristics of the drug and to clarify whether the two formulations are comparable before and after the change.

Timeline

Start
2023-09-19
Primary completion
2023-11-07
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject GenSci094 Protein / enzyme biologic 150 ug Subcutaneous

Indications